@article{Hannappe2022-fj,

title = {Mid-term impact of anti-vascular endothelial growth factor 

 agents on intraocular pressure},

author = {Marc-Antoine Hannappe and Florian Baudin and Anne-Sophie Mariet and Pierre-Henri Gabrielle and Louis Arnould and Alain M Bron and Catherine Creuzot-Garcher},

year  = {2022},

date = {2022-02-01},

journal = {J. Clin. Med.},

volume = {11},

number = {4},

pages = {946},

publisher = {MDPI AG},

abstract = {The effect of intraocular injections of anti-vascular 

 endothelial growth factor (VEGF) on intraocular pressure (IOP) 

 has not been clearly stated. We extracted data from the 

 electronic health records at Dijon University Hospital of 750 

 patients who were unilaterally injected with anti-VEGF agents 

 between March 2012 and March 2020. These were 

 treatment-naïve patients who had received at least three 

 injections of the same treatment (aflibercept, bevacizumab, or 

 ranibizumab) in one eye only, and had IOP measurements before 

 and after the injections. Fellow untreated eyes were used as 

 comparators. A clinically significant IOP rise was determined as 

 an IOP above 21 mmHg and an increase of at least 6 mmHg compared 

 to baseline, or the need for IOP-lowering agents. We found an 

 overall slight increase in IOP between treated and untreated 

 eyes at 6 months (+0.67 $±$ 3.33 mmHg, 95% confidence 

 interval 0.33–1.02, p},

keywords = {anti-VEGF agents; intraocular pressure; intravitreal injection},

pubstate = {published},

tppubtype = {article}

}